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Abstract
Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). In the murine
experimental autoimmune encephalomyelitis (EAE) model of MS, T regulatory (Treg) cell therapy has proved to be
beneficial, but generation of stable CNS-targeting Tregs needs further development. Here, we propose gene
engineering to achieve CNS-targeting Tregs from naïve CD4 cells and demonstrate their efficacy in the EAE model.
Methods: CD4+ T cells were modified utilizing a lentiviral vector system to express a chimeric antigen receptor
(CAR) targeting myelin oligodendrocyte glycoprotein (MOG) in trans with the murine FoxP3 gene that drives Treg
differentiation. The cells were evaluated in vitro for suppressive capacity and in C57BL/6 mice to treat EAE. Cells
were administered by intranasal (i.n.) cell delivery.
Results: The engineered Tregs demonstrated suppressive capacity in vitro and could efficiently access various
regions in the brain via i.n cell delivery. Clinical score 3 EAE mice were treated and the engineered Tregs
suppressed ongoing encephalomyelitis as demonstrated by reduced disease symptoms as well as decreased IL-12
and IFNgamma mRNAs in brain tissue. Immunohistochemical markers for myelination (MBP) and reactive
astrogliosis (GFAP) confirmed recovery in mice treated with engineered Tregs compared to controls. Symptom-free
mice were rechallenged with a second EAE-inducing inoculum but remained healthy, demonstrating the sustained
effect of engineered Tregs.
Conclusion: CNS-targeting Tregs delivered i.n. localized to the CNS and efficiently suppressed ongoing
inflammation leading to diminished disease symptoms.
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Background
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS) involving autoreactive T
cells recognizing myelin epitopes. Activated T cells in-
vade the CNS, recruit peripheral mononuclear phago-
cytes and demyelination in the brain and spinal cord
tissue, ultimately leading to impaired neuronal transmis-
sion [1]. T regulatory cells (Tregs) have the capacity to
regulate ongoing immune reactions and are important in
the control of autoimmunity [2,3]. Tregs exert their im-
munosuppressive functions via secretion of inhibitory
cytokines, by interfering with the metabolism of T cells
and/or in an undetermined contact-dependent manner.
Furthermore, Tregs block T cell activation indirectly via
their interaction with antigen-presenting cells (APCs),
preventing APC maturation and consequently downre-
gulate their expression of costimulatory molecules and
cytokine secretion [4,5]. Many studies have investigated
the role of Tregs and their suppressive function in MS
patients and despite some contradicting results, likely
due to the multiple definitions of Treg subclasses, it has
been concluded that their suppressive activities are
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impaired during disease progression [6-8]. MS patients
may therefore benefit from Treg cell therapy to restore
this insufficient immunosuppressive capacity.
It has also been demonstrated that Tregs play a critical
role in the protection and recovery of the animal model
of MS, experimental autoimmune encephalomyelitis
(EAE). Depletion of Tregs inhibits natural recovery from
EAE whereas transfer of Tregs to recipient mice reduces
disease severity [9,10]. Transfer of antigen-specific Tregs
derived from TCR transgenic mice was more effective
than polyclonal Tregs in controlling murine models of
both autoimmune gastritis [11] and MS [12]. However,
adequate numbers of antigen-specific Tregs are difficult
to achieve for adoptive transfer. A chimeric antigen re-
ceptor (CAR) was used to redirect Tregs to a desired
antigen in a colitis model [13,14]. Cultured Tregs may
change their suppressive phenotype posttreatment, and
this might be detrimental for patients. For example, Xu
and coworkers have reported that Tregs in the absence
of TGFβ can differentiate into Th17 cells, which are
considered an integral cause of autoimmune manifesta-
tions in MS [15]. Since FoxP3 is fundamental for the dif-
ferentiation and maintenance of Tregs, a stable
expression of FoxP3 by genetic engineering may block
Treg conversion into effector cells and thereby provide a
safer option for patients. In a model of arthritis, FoxP3
was coexpressed with an antigen-specific TCR to achieve
multiple stable targeting Tregs [16]. By co-expressing
FoxP3 with a chimeric antigen receptor (CAR) [17] tar-
geting myelin oligodendrocyte glycoprotein (MOG) in
naive CD4+ T cells we can generate sufficient numbers
of stable Tregs that localize to the CNS. The role of the
CARαMOG receptor is to attach the Treg to the vicinity
of MOG+oligodendrocytes to prevent immune attacks
against these cells.
In the present study, engineered Tregs were analyzed
for their suppressive function, capacity to localize to the
CNS upon intranasal (i.n) or intraperitoneal (i.p) cell de-
livery, and for their therapeutic capacity in EAE symp-
tomatic mice.
Materials and methods
Antibody production, purification and
immunohistochemistry
Hybridoma cell line 8–18 C5 [18] was cultured in RPMI
1640 medium supplemented with 10% fetal calf serum.
Antibodies were purified using protein A affinity chro-
matography (HiTrap MabSelect, GE Healthcare, Little
Chalfont, UK) following addition of 0.5 M trisodium cit-
rate (Sigma-Aldrich Corp., St Louis, MO, USA) to the
clarified supernatant. The column was washed with
500 mM sodium citrate pH 8.5 and the antibody fraction
was eluted with 0.1 M glycine (Sigma-Aldrich) at pH 2.7.
The eluate was neutralized using Tris-HCl (Sigma) at
pH 8 and concentrated using a JumboSep ultrafiltration
device and 10kD cutoff filter (Pall Gellman, WWR Inter-
national, Stockholm). Specificity of the antibody was
confirmed through Western blotting analyses of whole
mouse myelin and recombinant MOG.
For immunohistochemical MOG detection sections
from a naïve mouse brain were fixed in 4% paraformal-
dehyde and rinsed with PBS-Tween before addition of
peroxidase blocking reagent (EnVision, DakoCytoma-
tion, Glostrup, Denmark). Sections were first blocked
using 100 μl (1:100) Fc-receptor block (Serotec, Kidling-
ton, UK) and thereafter staining was performed with
200 μL (1:50) αMOG antibodies (8.18 C5, C. Linington)
followed by 200 μl (1:50) rabbit-α-mouse Ig (EnVision,
DakoCytomation) for 30 minutes each. AEC solution
(DakoCytomation) was applied for colour development
and sections were finally counterstained with hema-
toxylin prior to microscopic analysis.
Chimeric antigen receptor (CAR) construct
The CARαMOG-FoxP3 vector (Figure 1A) was con-
structed as follows: a single chain variable fragment
(scFv) was cloned from hybridoma (8.18 C5) producing
anti-rat myelin oligodendrocyte glycoprotein (MOG)
antibodies. The scFv was linked via an antibody hinge re-
gion to the transmembrane and intracellular part of a
CD3ζ chain, which was in turn fused to an intracellular
CD28 domain. The murine FoxP3 gene was inserted into
the construct and separated from the CAR gene by a
2A peptide (described in reference [19]). The final
CARαMOG-FoxP3 construct was inserted into the len-
tivector pRRL-CMV (kind gift from R Houeben, Leiden
University Medical Center, Netherlands). Lentiviruses
(Lenti-CARαMOG-Foxp3 and Lenti-Mock, Lenti-GFP)
were produced by co-transfecting 293FT cells with
pLP1, pLP2 and pLP/VSVG (Invitrogen, Paisley, UK).
Virus supernatants were harvested on days 2 and 3 and
concentrated by ultracentrifugation. The amino acid se-
quence for the CARαMOG receptor is given in Add-
itional file 1: Figure S1.
Genetic engineering of T cells
Murine naive CD4 cells were sorted using the MACS
bead system (Miltenyi, Bergisch, Germany) and presti-
mulated with an initial dose of 1 μg of both anti-CD3
and anti-CD28 immobilized antibodies (BD Biosciences,
San Diego, CA, USA) as well as IL-2 (R&D systems Inc.,
Minneapolis, MN, USA) for three days prior to viral
transduction, since a good viral gene transduction of T
cells require cycling cells. 50 μl of viral supernatants was
added to 5 × 105 stimulated CD4+ T cells in 100 μl
RPMI-1640 medium supplemented with 1% sodium
pyruvate, 1% nonessential amino acids, 10% fetal bovine
serum, 1% penicillin/streptomycin (all from Invitrogen,
Fransson et al. Journal of Neuroinflammation 2012, 9:112 Page 2 of 12
http://www.jneuroinflammation.com/content/9/1/112
Paisley Scotland) and 8 μg/ml Polybrene (Sigma-Aldrich
Corp., Saint Louis, MO, USA). Cells were incubated for
four hours at 37 °C, 5% CO2 followed by addition of
300 μl of media (as above) supplemented with 100U IL-
2. The following day, media (as above) was replaced with
fresh media supplemented with 80U IL-2. Cells were
cultured for seven days with addition of 80U of IL-2
every second day. Transduction efficiency was analyzed
three-to-six days post-transduction. Transduced cells
were incubated for 10 minutes at 4 °C with a FITC-
conjugated mAb specific for the IgG-kappa in the scFv
(BD Biosciences, San Diego, CA, USA), washed with
PBS and resuspended in 1% paraformaldehyde (PFA) in
PBS. Samples were analyzed for surface expression of
CAR or intracellular green fluorescent protein (GFP) ex-
pression using a FACScanton (BD Biosciences, San
Diego, CA, USA).
EAE induction and Treg cell administration
Female C57BL/6 mice were purchased from Taconic,
Lille Skensved, Denmark. Mice were housed in the De-
partment of Animal Resources facilities at Uppsala Uni-
versity and used at five to eight weeks of age. Studies
were approved by the regional animal ethics committee
in Uppsala (C28/10). EAE was induced by subcutaneous
(s.c.) immunization in both hind and front limbs with
200 μg MOG35-55 peptide emulsified in complete
Freunds’ adjuvant (CFA) (Difco Laboratories, Detroit,
MI, USA) containing 5 mg/mlMycobacterium tubercu-
losis. Pertussis toxin (100 ng i.p) (Sigma-Aldrich Corp.,
Saint Louis, MO, US) was given at the time of
immunization and a second dose two days later. Disease
severity was monitored according to the following scale:
0, no disease; 1, flaccid tail; 2, hind limb weakness; 3,
hind limb paralysis; 4, fore limb weakness; 5, moribund.
When the mean score value was 3 (usually at day 15),
mice were treated using cell therapy. Cells (1 × 105 CAR
or Mock-transduced Tregs diluted in 10uL PBS) or
phosphate-buffered saline (PBS) were administered i.n.
in 5μL PBS using a plastic catheter connected to a pip-
ette (polyethylene tube, Becton Dickinson, Franklin
Lakes, NJ, USA) inserted for 3 mm in both nasal nostrils
during anesthesia (0.05 to 0.1 mg ketalamine-xylazine
mixture/10 g body weight; ketamine 50 mg/ml, Pfizer
AB, Sollentuna, Sweden; xylazine 20 mg/ml, Bayer AG
Animal Health, Business Group, Leverkusen, Germany).
For i.p. cell therapy 1x105 cells (CAR or Mock-
transduced Tregs) diluted in 100 μL PBS were injected.
Mice were sacrificed with gaseous CO2 and brains were
excised and fixed either in ice-cold 4% phosphate-
Figure 1 CNS-targeting receptor and FoxP3 translation and function. (A) The CARαMOG-FoxP3 vector contains a scFv cloned from the
8.18 C5 hybridoma. The scFv is linked via an antibody hinge region to the transmembrane and intracellular part of a CD3 zeta chain. The zeta
chain is further fused to an intracellular CD28 domain. The murine FoxP3 gene was inserted into the construct after a 2A peptide sequence.
Upon translation, the whole expression cassette is translated into a CARFoxP3 fusion protein that is self-cleaved at the 2A site to produce the two
separate proteins CARαMOG and FoxP3. (B) CARαMOG and FoxP3 is transported to the cell surface and nucleus, respectively. At the cell surface
CARαMOG can bind to MOG+ cells to attach the Treg to those cells and prevent immune attacks on MOG+ cells such as oligodendrocytes in the
CNS. FoxP3 will drive the Treg phenotype by regulating gene transcription in the nucleus.
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buffered formaldehyde (pH7.4) or isopentane with dry-
ice for paraffin-embedding or frozen- sectioning, re-
spectively. Tissues embedded in low-melting paraffin
after grade scale alcohol dehydration and xylene treat-
ment were sectioned in the sagittal plane (4 μm) through
the brain, mounted on gelatine-coated glass and used for
immunohistochemistry.
Tissue localization of engineered Treg cells in naïve mice
1 × 104 GFP/CARαMOG-FoxP3-engineered CD4+ T cells
diluted in 5 μl PBS, Mock-transduced Tregs or PBS were
administered i.n in the right nostrils of naïve animals as
described above. Horizontal cryosections of the brain,
(10 μm) were air-dried and kept at −80 °C. Tissue sec-
tions at the same level were selected following a quick
staining with toluidine blue. Sections washed in cold
PBS were quenched with 0.3% H2O2 in methanol,
blocked with 2.5% normal horse serum for one hour fol-
lowed by staining with anti-GFP primary antibody
(1:300) ab390 (Abcam, Cambridge, UK) overnight at
4 °C. Thereafter, Alexa Fluor 488 anti-rabbit (1:200) sec-
ondary antibody was applied. Specificity controls for
immunostaining included sections stained in the ab-
sence of primary antibody and staining of sections from
a vehicle-treated mouse not receiving GFP+ cells. For
detection of DNA/nuclei sections were overlain with
Vectashield Mounting Medium containing 4′,6′-diamidino-
2-phenylindoledihydrochloride(DAPI) (Vector Laboratories,
Burlingame, CA, USA). Immunofluorescence images were
captured using a Leica DMRBE fluorescence microscope, a
digital camera (Nikon Dxm 1200 F Nikon Corp., Tokyo,
Japan) and Nikon ACT-1 version 2.62 software. All images
were processed in Adobe Photoshop and Illustrator CS4,
and green (GFP) and blue (DAPI) channel images were
merged using Photoshop software.
Immunohistochemistry for nerve damage and repair
For myelin basic protein (MBP) and glial fibrillary acidic
protein (GFAP) detection the avidin biotin complex
(ABC) method and 3,3′ diaminobenzidine (DAB) as
chromogen were used. Deparaffinized and rehydrated sa-
gittal sections were rinsed with PBS and PBS-T. For
GFAP antigen, demasking was performed in a micro-
wave using 10 mM sodium citrate buffer. Endogenous
peroxidase activity was blocked with 1 to 3% H2O2 in
PBS-T and nonspecific background staining was blocked
with 4% BSA in PBS. Sections were incubated overnight
with the primary antibodies (MBP 1:200 Abcam, Cam-
bridge, UK; GFAP 1:400 Millipore, Billerica, MA. USA).
After washing, the sections were incubated with a bioti-
nylated secondary antibody and then with ABC complex
(both from Vector Laboratories, Burlingame, CA, USA).
Immunoreactions were visualized with DAB (Sigma-
Aldrich Corp., St.Louis, MO, USA). Sections were
counterstained with hematoxylin. Finally, the tissue sec-
tions were rinsed gradually through a graded alcohol
series and finally in xylene, and mounted immediately
after with Pertex (Histolab, Göteborg, Sweden). The tis-
sue sections were analyzed using an Olympus micro-
scope (Olympus, Tokyo, Japan) and images were
captured using a digital camera as described above.
Results were analyzed in a blinded mode scoring the
level of staining as weak, moderate or strong. Digital
images were collected at the same time using identical
settings with respect to image exposure time and image
compensation setting. Images were processed using
Adobe Photoshop and Illustrator CS4.
Treg suppression assay
For in vitro suppression assays, 3 × 104 CARαMOG-
FoxP3 or Mock-transduced CD4+ T cells irradiated at
25 Gy were mixed in different ratios with αCD3/IL-2-sti-
mulated splenocytes derived from a naïve healthy mouse
in a total volume of 200 μl/well. The RPMI-1640
medium was supplemented with 0.1% sodium pyruvate,
1% nonessential amino acids, 1% Hepes buffer, 1% β-
mercaptoethanol, 10% fetal bovine serum and 1% peni-
cillin/streptomycin (all from Invitrogen, Paisley, UK).
Cells were seeded in 96-well rounded-bottom tissue cul-
ture treated plates (Sarstedt, Newton, NC, USA) and
incubated for 48 hours, after which 1 μCi of 3H-thymi-
dine (PerkinElmer, Waltham, MA, USA) was added per
well. Cells were incubated for an additional eight hours
before harvest to filters. The incorporated 3H-thymidine
was measured using a β-counter (Perkin Elmer Life Sci-
ence, Turku, Finland). In some experiments, murine
2.5 × 104 macrophages or 2.5 × 104 MOG+ cells were
added to cultures with CARαMOG-FoxP3-transduced
CD4+ T cells in a 1:1 ratio. Activated macrophages were
obtained via plastic adherence of splenocytes. Monocytes
were activated by 1 μg lipopolysaccharide (LPS) and
matured during one week in RPMI-1640 medium sup-
plemented with 1% sodium pyruvate, 1% nonessential
amino acids, 10% fetal bovine serum and 1% penicillin/
streptomycin. MOG+ cells were generated via lentiviral
gene transfer of murine MOG to 293 T cells. MOG ex-
pression was confirmed by histochemistry using αMOG
antibodies (clone 8.18 C5) as described above.
Quantitative PCR
Brain biopsies from EAE mice treated i.n. with CAR,
Mock-transduced Tregs or PBS, respectively, were treated
with tissue lysis buffer ATL (Qiagen, Hilden, Germany) at
60 °C for three hours followed by DNA purification using
High Pure Viral Nucleic Acid kit (Roche, Basel Switzer-
land). cDNA was obtained using the Superscript II Re-
verse Transcriptase kit (Invitrogen, Paisley, UK).
Quantitative-PCR was performed using the real-time
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system (iCycler, Bio-Rad Laboratories Inc., Hercules, CA,
USA). The reaction was performed with SYBR green mix
(BioRad). Primer pairs for β-actin were designed as fol-
lows: forward 5′-TTCCTTCCCAGAGTTCTTCCAC, re-
verse 5′-CCAGGATGGCCCATCGGATAAG (Cybergene
AB, Huddinge, Sweden). Primers to detect IL-12 and IFNγ
were designed as described previously [19,20]. In order to
correct for variable amounts of DNA content between
samples, all copy numbers were corrected to β-s. The
mRNA copy number in 2 μL cDNA was evaluated in the
experiments.
Statistics
Significant differences between groups were calculated
using GraphPad Software (La Jolla, CA, USA). The
method for each individual calculation is stated in the
Figure Legends. *P< 0.05, **P< 0.01, ***P< 0.001.
Results
Phenotype and function of engineered Tregs
Antibodies produced and purified from the 8.18 C5
hybridoma were tested for cross-reactivity to murine
MOG. The selected MOG antibody detected murine
MOG in the brains of naive mice (Figure 2A). A scFv
from the 8.18 C5 hybridoma was generated and cloned
into a murine CAR receptor and was then inserted in
tandem with murine FoxP3 into a lentiviral system to
produce CARαMOG-FoxP3 viruses. Sorted and pre-
activated naive CD4+ T cells were successfully trans-
duced with the CARαMOG-FoxP3 lentivectors (CAR
Tregs). Prior to stimulation and transduction CD4+ T
cells are sorted from splenocytes. Transduced and
expanded cells remain CD4 positive. Post-gene transfer
the scFv of the CARαMOG receptor could be detected
on the cell surface of approximately 10 to 15% of cells
(Figure 2B) and the FoxP3 mRNA levels in the engi-
neered cells were two-fold greater than that of
Mock-transduced T cells (CD4 Mock) which include a
population of naturally occurring Tregs (Figure 2C). Nat-
ural Tregs suppress activated T cells in a non-TCR
restricted manner by contact dependent and independent
mechanisms. CAR Tregs suppressed polyclonally stimu-
lated T cells (P< 0.05) at a 1:2 ratio (Figure 2D) demon-
strating the gained suppressive function. The role of
the CARαMOG receptor is to attach the Treg to the
vicinity of MOG+oligodendrocytes to prevent im-
mune attacks against these cells (Figure 1B). To
investigate that the CAR Tregs retained their sup-
pressive function upon binding to MOG+ cells, the
suppressive function of polyclonally stimulated T cells
were analyzed in cocultures with MOG+ cells. In
Figure 2D it is demonstrated that the CAR Tregs con-
tinue to suppress T cell proliferation in the presence of
MOG+ cells. Further, activated murine macrophages
may produce cytokines or other factors that block the
function of the CAR Tregs. Activated macrophages are
part of the MS pathology and therefore CAR Tregs
were cultured with such cells to determine if CAR
Tregs were still suppressive against T cells. In our assay
CAR Tregs were still able to suppress effector T cell
proliferation in the presence of activated macrophages
(Figure 2D; P< 0.05).
Figure 2 Engineered Tregs express CAR and FoxP3. (A) Antibodies from the 8.18 C5 hybridoma cross-reacted with murine myelin as
demonstrated by immunohistochemistry (red colour expression). (B) CD4+T cells transduced with CARαMOG-FoxP3 lentivectors (CAR Tregs) were
stained with fluorescein isothiocyanate (FITC)-conjugated antibodies and analyzed for surface expression of the scFv by flow cytometry. (C) FoxP3
copy number in transduced cells analyzed by quantitative PCR analysis. Expression of FoxP3 is significantly higher than both CD4-mock and naïve
CD4+T cells (P< 0,05) as analyzed by Mann-Whitney using GraphPad prism software. The expression experiments were repeated for every cell
generation with similar result. (D) CAR Tregs were mixed with αCD3/IL-2-stimulated T cells at a1:2 ratio and analyzed for suppressive ability in a
thymidine-based assay. CAR Tregs were able to suppress activated T-cells (P< 0.05). CAR Tregs suppressed αCD3/IL-2-stimulated T cells in the
presence of activated macrophages (P< 0.05) or MOG-expressing cells (P< 0.05). The experiments were repeated and statistical differences
analyzed by Mann-Whitney test using GraphPad prism software.
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In vivo localization of Tregs to the brain
CAR Tregs co-expressing GFP and CARαMOG-FoxP3
were used to evaluate in vivo targeting upon i.n. cell de-
livery in naïve mice. The overall localization of GFP im-
munofluorescence is illustrated in the schematic drawing
in Figure 3. The green fluorescence was mainly localized
in clusters of cells in the granular layer and the external
plexiform layer of the olfactory bulb (Figure 3B, C), in
the lateral septal nucleus (Figure 3E), in the central med-
ial thalamic nucleus (Figure 3F), in the ectorhinal cortex
(Figure 3H), in the medial genic nucleus (Figure 3I) and
in the Purkinje cell layer and white matter of the cere-
bellum (Figure 3K, L). In addition, green immunofluor-
escence was observed in anterior olfactory nucleus and
anterior orbital cortex (data not included). The green
immunofluorescence was only observed in the soma and
was preferentially present in the perinuclear part
(Figure 3F, I). Although a unilateral dose of cells was
given, the localization of immunofluorescence occurred
both on the ipsilateral and contralateral sides of the
brain. In the vehicle control animal no, or extremely
weak, green background immunofluorescence could be
detected (Figure 3A, D, G, J). The localization of im-
munofluorescence is summarized in Table 1.
CNS-targeting CAR Tregs suppress active EAE
At the peak of EAE inflammation 1 × 105 cells of each
CAR Tregs and Mock CD4+ T cells, or PBS alone, was
administered i.n. or i.p. to 10 mice per group. EAE mice
responded well to cell therapy independently of adminis-
tration route (Figure 4A to C). The EAE scores were ini-
tially reduced upon i.n delivery of either CAR Tregs or
Mock CD4+ T cells. Seven days post-treatment only the
CAR Treg treatment group exhibited a continuous re-
duction of clinical disease symptoms and at day 25 all
mice (n = 10) were symptom-free (Figure 4A). At the
same time point, only a few mice in the Mock control
group (n = 5) that contained a normal rate of natural
Figure 3 Engineered Tregs localize to the CNS when administered intranasally in naive mice. Treg cells were administered intranasally in
the right nostril and the distribution of green fluorescent protein (GFP) in horizontal cryosections of the brain of naïve mice was studied 24 hours
after the delivery. The schematic drawing describes a selective immunofluorescence in various brain regions (green spots). GFP
immunofluorescence is present in the granular and to a lower extent in the external plexiform layer of the olfactory bulb (B, C), lateral septal
nucleus (E), central medial thalamic nucleus (F), ectorhinal cortex (H), medial genic nucleus (I) and cerebellum (K, L) of a CAR Treg-treated naïve
mouse. Corresponding areas showing no GFP fluorescence in a PBS-treated naïve mouse are (A, D, G, J). Enlargements of areas in olfactory bulb
and cerebellum (as indicated by boxes) are depicted in C and L. Detail of GFP immunofluorescence in the central medial thalamic nucleus and
medial genic nucleus (F, I). Cell nuclei (blue) are stained with DAPI Original magnification 10× (A, B, D, E, G, H, J, K) and 40× (C, F, I, L).
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Tregs (see Figure 2C) were classified as being healthy.
The remaining mice exhibited symptoms corresponding
to a clinical score of 3. At day 30 also, the Mock control
group had a good performance score and significantly
differed from PBS controls (P< 0.05). At this time point
healthy mice from each group, except the PBS treatment
that did not cure mice, were re-challenged with an add-
itional EAE-inducing inoculum using CFA and pertussis
toxin. In the CD4+ Mock group all mice developed EAE
symptoms by day two. In the CAR Treg group only one
mouse developed weak EAE (score 1) (Figure 4B).
Upon examination of immunohistochemical markers
for myelination (MBP) and reactive astrogliosis (GFAP),
mice in the CAR Treg group exhibited confirmed recov-
ery 15 days post-treatment (Figure 5). Reactive astroglio-
sis was evaluated in the olfactory bulb (Figure 5A-C),
corpus callosum (Figure 5D-F), cerebellum (Figure 5G-I)
and hippocampus (data not included). An increased
GFAP staining was detected in both CAR Treg- and
CD4+ Mock-treated EAE mice as compared to PBS-
treated EAE mice. The level of staining was higher in
CAR Treg-treated EAE mice as compared to CD4+
Mock-treated EAE in all areas except the olfactory
bulb, where the level of staining was lower (Figure 5B,
C). Myelination was evaluated in the brain stem
(Figure 5J-L), hippocampus (Figure 5M - O) and cerebel-
lum (Figure 5P-R), corpus callosum and olfactory bulb
(data not included). The degree of myelination, as indi-
cated by MBP staining in PBS-treated EAE mice compared
to CAR Treg-treated mice in brain stem and in cerebel-
lum, was slightly stronger (Figure 5J and P), whereas
staining was weak or absent in the others areas. MBP
staining in the brain of CD4+ Mock-treated EAE mice
was lower compared to that in CAR Treg-treated mice.
In addition to the noted markers of recovery and mye-
lination, the levels of Th1-associated cytokines were
measured by quantitative PCR analysis of tissues from
the same brains. These results revealed lower levels of
the T cell associated IFNγ mRNA in mice treated with
CAR Tregs compared to control brain tissue such as
mice treated with PBS or Mock-transduced cells
(Figure 6). IL-12, on the other hand, is only detected
in PBS mice demonstrating that DC maturation may
be compromised in both CAR Treg and Mock groups.
Conclusions
Tregs are developed in the thymus (natural Tregs) or in
the periphery in response to cytokines such as TGFβ. In
autoimmunity, the patients may have genetic variations
leading to reduced, or nonfunctional, Tregs. They may,
as well, have deficits in other signalling pathways that
affect the Treg suppression mechanisms. Severe systemic
autoimmunity, such as immune polyendocrinopathy en-
teropathy X-linked syndrome (IPEX) shows FoxP3 muta-
tions that block the Treg differentiation. It is difficult to
dissect if natural or peripherally derived Tregs are the
most important for controlling autoimmunity, but since
the natural Tregs commonly have affinity for self-
antigens these Tregs likely have a predominant role in
blocking emerging autoimmunity [2,3,5]. In the current
investigation, CD4+ T cells were modified utilizing a len-
tiviral vector system to express a chimeric antigen recep-
tor (CAR) targeting myelin oligodendrocyte glycoprotein
(MOG) in trans with the murine FoxP3 gene that drives
Treg differentiation. In that sense, the gene-engineered
Tregs are peripherally derived cells. However, they ex-
press FoxP3 and have a strong affinity to a self-antigen
via the CAR receptor, so they are also similar to natural
Tregs. The genetically engineered Tregs demonstrated
suppressive capacity in vitro and reduced disease symp-
toms in mice with active EAE in vivo. The suppressive
effects of Tregs in murine models of autoimmune path-
ology have provoked an interest in clinical translation.
Transfer of Tregs into animals with autoimmunity pro-
vides protection but, to date, there are no records of
clinical trials using adoptive transfer of Tregs in humans
with autoimmune diseases. Tregs have, however, been
used in the clinic to induce transplantation tolerance
[21]. One problem with Tregs is sorting and expanding
the population since FoxP3, the most reliable marker, is
only present intranuclearly. It is also a major challenge
to produce antigen-specific Tregs for cell therapy since
that would require antigen-stimulation for an extended
time. However, Tregs can be generated from naive CD4+
T cells by gene transfer of FoxP3 [22]. Using retroviral
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gene transfer of murine FoxP3 into CD4+CD25- T cells,
Chai and coworkers generated Tregs and used them in
an animal model for transplantation with promising
results [23], and this was later confirmed using a lenti-
viral vector system [24].
Genetically engineered and cultured Tregs have been
evaluated for treatment efficacy in a wide variety of
adoptive transfer models of autoimmune diseases
[9,23,25-27]. However, systemically delivered Tregs may
result in recipient failure to respond to infectious dis-
ease, or they may not accumulate in sufficient amounts
at the correct location. Mekala and co-workers redir-
ected murine CD4+CD25+ Tregs by using a chimeric
antigen-MHC/ζ receptor targeting myelin basic protein
(MBP) in the EAE model. In their study MBP-specific
Tregs were able to suppress EAE-inflammation [28].
Hombach and coworkers have redirected human CD4
+CD25+ Tregs by using retroviral transfer of a recombin-
ant anti-CEA-immunoreceptor to target the inflamed in-
testine, with promising results [29]. In the present study,
we have used chimeric antigen T cell receptors, so-called
CARs, to direct the T cells to MOG present in the CNS
[17]. The construct also contained murine FoxP3 to
drive the transduced CD4+ T cells toward a Treg stable
phenotype.
The engineered Tregs expressed both CAR and FoxP3,
and in assays testing their function they significantly
decreased T cell proliferation even in the presence of
LPS-stimulated macrophages that are thought to take
part in the transformation of Tregs into Th17 effector
cells due to their production of activating cytokines
[30,31]. Binding to MOG+ cells by their CAR did not
change their suppressive function either, as indicated by
co-culturing CAR Tregs, MOG+ cells and stimulated T
cells. Activated macrophages are part of the pathology of
MS and the CAR T cells were challenged with such cells
in the suppressive assays to exclude that they lose their
function in the presence of macrophages. There was a
somewhat decreased suppressive capacity noted in these
groups, but it did not reach significance.
Figure 4 CNS-targeting Tregs can reduce EAE symptoms. (A)
Ten mice in three groups were given 1× 105 CAR Tregs, CD4+ Mock
T cells or PBS alone by i.n. administration at the peak of EAE
inflammation (15 days post-EAE immunization) and thereafter were
monitored for EAE symptoms. Ten days post cell treatment all EAE
mice in the CAR Treg group were cured (P< 0.001). At end point
(15 days post cell treatment) four out of ten EAE mice in the
Mock-treated group still exhibited EAE symptoms. The experiment
was repeated three times with similar results. (B) Symptom-free
mice from each treatment group were given a second dose of
EAE-inducing inoculum and monitored for EAE symptoms. CAR
Treg-treated mice were able to resist EAE inflammation to a higher
extent than CD4+ Mock-treated mice (P< 0.001). Pooled data from
six EAE mice (three/group from two separate experiments) are
shown in the figure. Scores for individual mice are shown separately
in the figure. (C) Ten EAE mice in three groups were administered
1x105 CAR Tregs, CD4+ Mock T cells or PBS alone by i.p. injection
at peak of EAE inflammation (day 15). At end point (day 15
post-treatment) all mice in the CAR Τreg group were cured but six
out of ten mice in the Mock CD4+ T cell group still exhibited EAE
symptoms. Statistics are analyzed with Mann-Whitney test using
GraphPad prism software. *P< 0.05, **P< 0.01, ***P< 0.001.
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Figure 5 Astrogliosis and remyelination after intranasal administration of CNS-targeting Treg. Mice in three groups were given 1 × 105
CAR Tregs, CD4+ Mock T cells or PBS alone by intranasal administration at the peak of EAE inflammation (15 days post-EAE immunization). Fifteen
days post cell treatment the mice were killed and brain sections from each group (CAR Tregs, Mock CD4+ T cell and PBS) were analyzed for
reactive astroglisosis using glial acidic fibrillary protein (GFAP) (A-I) and myelination using myelin basic protein (MBP) (J-R). GFAP was evaluated in
olfactory bulb (A-C), corpus callosum (D-F), and cerebellum (G-I) of brain sagittal section from PBS, Mock CD4+ T cell and CAR Τreg-treated EAE
mice. In the olfactory bulb of mice treated with Mock CD4+ T cells there was a strong staining for GFAP whereas this area in PBS-treated mice (A)
and of CAR Treg-treated mice (C) exhibited a weak and moderate staining, respectively. There is an extremely weak staining in PBS-treated EAE
mice, moderate staining in Mock CD4+ T cell-treated EAE mice and strong staining in CAR Treg-treated EAE mice for corpus callosum and
cerebellum. MBP was evaluated in brain stem (J-L), hippocampus (M-O) and cerebellum (P-R) of brain sagittal sections in PBS, Mock CD4+ T cell
and CAR Treg-treated EAE mice. In the brain stem and cerebellum of mice treated with CAR Tregs, there was a moderate staining for MBP (L, R)
whereas the brain stem of Mock-treated mice (K,Q) and PBS-treated mice (J,P) exhibited a weak and strong staining, respectively. There is an
extremely weak staining in PBS-treated EAE mice, a moderate staining in Mock CD4+ T cell-treated EAE mice and strong staining in CAR
Treg-treated EAE mice for hippocampus. Original magnification 10×.
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GFP-expressing CAR Tregs were then used to track
the immunofluorescence in the brain 24 hours after an i.
n. cell administration. Analysis of GFP-positive immuno-
fluorescence in the brains of naïve mice revealed clusters
of fluorescent cells in various brain areas. Immunofluor-
escence was localized, for instance, in the olfactory bulb,
orbital and ectorhinal cortex, but also in the Purkinje
cells and white matter of the cerebellum. The selective
GFP immunofluorescence of the Purkinje cells and other
cells that are not matching was detected in the cerebel-
lum. The selective GPF immunofluorescence of the Pur-
kinje cells, and/or other cells that are not matching the
features of Tregs, may possibly be related to a vesicular
transfer and uptake of the GFP protein. Further investi-
gations are needed to establish that the observed im-
munofluorescence is due to GFP-expressing CAR Tregs,
fusion with other cells or cell debris that has been taken
up by other cells.
A previous study has described that myelin-specific
Tregs accumulate in the CNS but fail to control auto-
immune inflammation [32]. This depended on the resist-
ance of local effector T cells to suppression, partly due
to IL-6 and TNF production. However, McGeachy and
coworkers described that transfer of low numbers of
CD4+CD25+ cells from the CNS of recovering mice be-
fore EAE reinduction reduces disease severity in recipi-
ents [33], demonstrating the potential of Treg therapy in
EAE. Our present results clearly demonstrated that
Tregs (engineered or not) could reduce disease symp-
toms in mice with active EAE upon both i.n. and i.p. de-
livery. Hence the effector cell resistance to Treg
suppression demonstrated by Korn and coworkers [34]
may not occur using engineered Tregs. However, the
mock-transduced CD4+ T cells containing a mixture of
natural FoxP3+ Tregs and naïve T cells did not com-
pletely cure EAE. When delivered i.n. mice treated with
CD4+ Mock T cells could recover from EAE nearly as
well as with CNS-targeted CAR Tregs, but the effect
was not optimal, since only CAR Tregs could generate
mice resistant to an additional EAE challenge 30 days
post-treatment. If delivered i.p. the difference between
targeted and nontargeted Tregs became more evident.
Immunohistochemical evaluation of recovery (GFAP)
and myelination (MBP) of axons in the brain confirmed
recovery and revealed decreased damage to axons in
mouse brains treated with CAR Tregs compared to con-
trol groups. Furthermore, mice treated with CAR Tregs
had reduced levels of effector cytokines (IL-12 and IFNγ)
in brain tissue compared to both mice treated with
crude T cells and PBS, thus indicating the different qual-
ities of the targeted and non-targeted Tregs in suppres-
sing inflammation.
A problem with adoptive transfer of Tregs is the inad-
equate number of cells reaching the target. Cell numbers
decrease during migration and the risk of therapeutic
cells ending up in vital and/or reproductive organs must
be taken into consideration. The olfactory pathways have
been extensively investigated as potential entry for
pharmaceutical drugs into the brain [35,36]. Recently, i.n
delivery has been examined as a potential route of ad-
ministration for transplantation of cells into the brain
with the advantage of reducing cell doses required for
therapeutic efficacy while, at the same time, decreasing
systemic exposure [32,37,38]. In this study, we further
demonstrated intranasal administration of engineered
GFP +Treg cells carrying a MOG-targeting receptor can
be delivered via the nostrils and access the brain.
A migration of engineered Treg in the olfactory path-
ways to the brain may occur via extracellular channels
comprising olfactory ensheathing cells surrounding the
olfactory neurons or via perivascular spaces from the
nose to the brain. In addition, a migration into the gen-
eral blood circulation cannot be excluded since the nasal
mucosa is highly vascularized. A previous report demon-
strated migration of cells from the nasal mucosa through
the cribriform plate along the olfactory neural pathway
into the brain and cerebrospinal fluid (CSF) following
i.n. cell administration [32]. In that study, only a low
number of cells were tracked up to one hour post-
instillation. In the present study, we observed clusters
of immunofluorescent cells in the brain 24 hours post-
instillation in naïve mice. Because EAE mice treated
Figure 6 Decreased expression of effector cytokines in
CNS-targeting CAR Treg-treated brain. Mice in three groups were
given 1 × 105 CAR Tregs, CD4+ Mock T cells or PBS alone by i.n.
administration at the peak of EAE inflammation (15 days post-EAE
immunization). Fifteen days post cell treatment, brain biopsies from
five EAE mice per group (CAR Tregs, Mock CD4+ T cells and PBS)
were analyzed for expression of effector cytokines (IL-12 and IFNγ)
by quantitative RT-PCR. Error bars represent standard error of the
mean (SEM).
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once with CAR Tregs were still protected against an
additional EAE rechallenge the cells may still be intact
>30 days post initial cell therapy, but other explana-
tions are possible. Extrapolating to the human situation,
the concept presented in the current paper could facili-
tate administration of therapeutic cells without com-
promising the patient’s safety or the number of cells
reaching its target. In summary, i.n. cell administration
of CNS-targeted CAR Tregs can be delivered to the
brain using i.n. cell administration and efficiently ham-
per the disease symptoms as well as protect against an
additional EAE challenge. The novel findings in this re-
port warrant clinical translation.
Additional file
Additional file 1: Figure S1. The amino acid sequence of the
expressed CAR targeting MOG is shown in the figure.
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